Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims against Replimune Group, Inc., following significant stock losses. The firm is particularly focused on assisting investors who experienced losses exceeding $50,000 between November 22, 2024, and July 21, 2025. Those affected are invited to reach out to partner Josh Wilson for a consultation regarding their legal options.
The deadline for investors to seek lead plaintiff status in a federal securities class action against Replimune is September 22, 2025. The case arises from allegations that Replimune executives made misleading statements concerning the IGNYTE trial, which was deemed inadequate by the U.S. Food and Drug Administration (FDA). The outcome of the trial directly impacted the company’s business representation, which was found to be materially false or misleading. On July 22, 2025, Replimune revealed that it received a Complete Response Letter from the FDA stating that its application for a biologics license for the treatment of advanced melanoma could not be approved in its current form. This announcement resulted in a drastic drop of over 73% in Replimune’s stock price.
Investors who wish to discuss their eligibility to become lead plaintiff or share in any potential recovery should consider reaching out to the firm or visiting their website for further information. The law firm encourages anyone with relevant insights or information about Replimune’s conduct, including former employees and whistleblowers, to come forward.
The situation highlights the importance of transparency and accountability in corporate governance, as the legal ramifications could lead to significant changes or reforms in how companies represent their clinical trial results. Despite the challenging circumstances, it’s crucial for investors to know their rights and seek legal counsel to explore their options for potential recovery.